Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...

Descripció completa

Dades bibliogràfiques
Autors principals: Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba
Format: Article
Idioma:English
Publicat: SAGE Publishing 2016-03-01
Col·lecció:Therapeutic Advances in Gastroenterology
Accés en línia:https://doi.org/10.1177/1756283X15621232

Internet

https://doi.org/10.1177/1756283X15621232

Ítems similars